Revolution, Ascendis, Arrowhead among RBC's top M&A candidates in biotech
Source: SeekingAlpha
2026-03-19 14:37:43 ET
More on Revolution Medicines, Ascendis Pharma, etc.
- Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
- Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL - Slideshow
- This One Data Readout Could Make Or Break Revolution Medicines
- Ascendis Pharma wins FDA approval for navepegritide for achondroplasia
- Kymera outlines plans for KT-621 Phase IIb data in 2027 as cash runway extends into 2029
Read the full article on Seeking Alpha
For further details see:
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech
Vertex Pharmaceuticals Incorporated
NASDAQ: VRTX
VRTX Trading
0.83% G/L:
$442.47 Last:
20,295 Volume:
$442.35 Open:
VRTX Latest News
April 14, 2026 04:05:00 am
Trump's Team Says Don't Worry About Rising Inflation. Here Are 3 Stocks to Buy If They're Wrong.VRTX Stock Data
$118,425,801,558
253,211,393
0.21%
875
N/A
Biotechnology & Life Sciences
Healthcare
US
Boston
